Ambulatory surgery centers and hospital outpatient surgery units handle some of the most divertible drugs in healthcare — fentanyl, hydromorphone, midazolam, propofol — with none of the infrastructure a hospital pharmacy provides. There is often no on-site pharmacist, no pharmacy inventory system, and a small clinical team where the same people order, stock, administer, document waste, and reconcile. That is a diversion control problem wearing a business-model disguise.

Why ASCs Are Different

  • No pharmacist on site. A hospital's pharmacy is the natural control point for ordering, storage, and reconciliation. In an ASC, responsibility usually lands on a designated nurse or anesthesia provider — often the same people administering the drugs.
  • Separation of duties is hard with a small team. When four people run a center, the person who administers is often the person who documents the waste and the person who counts at the end of the day.
  • Anesthesia is the classic vector. Providers who control their own controlled-substance kits can forge waste records, substitute saline for fentanyl or morphine, or pocket partial doses — and in a busy ASC day, no one watches the anesthesia cart.
  • Less regulatory friction day-to-day. DEA inspects hospitals and retail pharmacies more often than ASCs, which means weaknesses can persist for years without an external challenge.

What the Rules Already Require

ASCs that participate in Medicare must meet the Conditions for Coverage in 42 CFR Part 416. The pharmaceutical services condition (§416.48) requires the center to provide drugs and biologicals in a safe and effective manner, in accordance with accepted professional practice, and under the direction of an individual designated as responsible for pharmaceutical services. Surveyors and accreditors expect the center to be able to demonstrate accountability for its controlled substances — secure storage, accurate records, and the ability to identify loss or diversion. Separate from Medicare, every ASC that holds a DEA registration is subject to the same CSA security, recordkeeping, and reporting obligations as any other registrant.

Trade coverage of ASC diversion — such as ASC News' 2025 feature on unchecked access — and professional guidance from organizations like AORN make the same point: the gap is real, and the fixes are known.

Where Diversion Hides in ASC Workflows

  • Waste documentation. "Wasted" fentanyl drawn but not used, documented by the same person who administered it, with no witness and no verification.
  • Anesthesia kit integrity. Kits stocked and returned by the same provider, with counts that never quite match and nobody reconciling.
  • End-of-day counts done by the people who used the drugs. A count is only a control if the counter is independent.
  • Unsecured storage between cases. In a busy center, the med room door gets propped open and the anesthesia cart rolls into a corner.
  • No behavioral monitoring. With no pharmacy or compliance team on site, the classic red flags — volunteering for extra cases, disappearing after procedures, insisting on managing the narcotics — have no natural owner to notice them.

Controls That Work Without a Pharmacist On Site

  • Assign one accountable person — and separate the duties. Designate an individual responsible for pharmaceutical services, and make sure the person who administers isn't the only one who documents waste or closes the count.
  • Two-person waste witnessing. Require a second clinician to observe and co-sign controlled-substance waste disposal — the single highest-leverage fix for the anesthesia vector.
  • Anesthesia kit accountability. Stock kits in a secure location with documented issue and return; reconcile returns against usage and waste before the provider leaves.
  • Independent daily counts. Have a manager or nurse who did not use the drugs perform the end-of-day count and variance sign-off.
  • Camera coverage of storage and wasting areas with a retention and review policy — footage is what converts a suspicion into a finding.
  • Periodic external review. If the center belongs to a hospital system, the system's diversion program should cover owned ASCs. Freestanding centers should schedule an annual controlled-substance audit by someone outside the daily team.

If You Run a Hospital System

Hospital-owned ASCs and outpatient surgery units are often the blind spot of an otherwise mature diversion program. Extend the program explicitly: same policies, same surveillance queries on the data you can access, same reporting channel, same audit calendar. The case that surfaces in your ASC should land in the same committee review as one from the main OR — not be discovered three years later by a DEA inspector.

Related Reading